Akoya Biosciences, Team SAMBAI announce selection of PhenoCycler-Fusion

Akoya Biosciences (AKYA) and SAMBAI announced that Akoya’s PhenoCycler-Fusion system will be the foundational spatial proteomics technology used to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research. “We are excited that the PhenoCycler-Fusion is the spatial proteomics technology of choice for analyzing thousands of patient samples as part of this important initiative,” said Brian McKelligon, CEO of Akoya Biosciences. “A study of this size demands the high plex and high throughput of our solutions to generate data at the scale needed. We are honored to play a role in defining the factors that influence disparate outcomes in underserved populations.”